Research programme: protein kinase inhibitors - Roche
Latest Information Update: 28 Aug 2024
At a glance
- Originator Reverie Labs; Roche
- Developer Roche
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer